MRSA Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The MRSA testing market size was valued at USD 3.76 billion in 2025 and is estimated to grow from USD 3.99 billion in 2026 to reach USD 5.39 billion by 2031, at a CAGR of 6.20% during the forecast period (2026-2031). This report is segmented by Test Type (Molecular Diagnostic, Immunodiagnostic, Culture-Based, Others), Product Type (Instruments, Reagents and Kits), End User (Hospitals and Clinics, Diagnostic Laboratories, Academic Institutes, Pharma and CRO Labs, Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global MRSA Testing Market Trends and Insights

Rising Demand for Rapid Infection-Control Decisions

Turnaround time has become a key purchasing consideration in the MRSA testing market. A 2025 comparative study found that the Eazyplex MRSA Plus LAMP assay identified MRSA within 1 hour of positive blood-culture processing, with 100% sensitivity and specificity across 109 blood cultures. This supports same-shift isolation decisions, compared with culture workflows that may require 48 hours. The study found inappropriate empirical therapy in 47% of patients with MRSA bacteremia, while more than 90% of methicillin-susceptible cases received unnecessarily broad-spectrum treatment. Pharmacist-led MRSA nasal PCR protocols have reduced empirical vancomycin duration, and active surveillance guidance indicates that clinical cultures alone can understate total hospital MRSA prevalence by up to 85%.

Growth of Automated Sample-to-Answer Molecular Platforms

The MRSA testing market is moving from open PCR workflows toward enclosed systems that integrate sample processing and detection. These platforms reduce reliance on specialist microbiology staff and extend molecular testing to smaller hospitals. A 2025 Lab on a Chip study described a compact platform that detected MRSA in human serum at 1 CFU per reaction within 45 minutes, integrating bacterial lysis, nucleic-acid purification, and colorimetric LAMP on a single chip. A 2025 meta-analysis reported a pooled sensitivity of 99% and a specificity of 100% for CRISPR-based MRSA detection across clinical samples. As automated systems expand into dialysis and long-term-care settings, instrument placements can increase recurring reagent demand. At the same time, FDA requirements for Class II MRSA nucleic-acid amplification devices establish a validation threshold for new systems.

High Per-Test Cost and Capital Intensity of Molecular Systems

Closed-cartridge PCR systems have higher reagent costs than chromogenic culture media, limiting adoption in budget-constrained laboratories. High-throughput automated systems may require capital expenditures ranging from the mid-six figures to the low-seven figures in USD, in addition to service agreements, trained personnel, quality processes, and recurring cartridge supplies. Community hospitals and long-term care facilities may lack the testing volumes required to justify this investment. A WHO 2025 analysis found that automated molecular systems were primarily concentrated in Level III and IV laboratories in high-income countries.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Active Surveillance in High-Risk Care Pathways
• Digital Epidemiology and Community-Associated Detection Needs
• Reimbursement and Screening-Policy Variability

Segment Analysis

Molecular diagnostic tests held a 48.96% share of the MRSA testing market in 2025, driven by cartridge-based PCR platforms for mecA and mecC detection in nasal swabs, blood cultures, and skin and soft tissue specimens. These systems support rapid testing in high-acuity and perioperative care settings. Culture-based tests remain important for antibiotic susceptibility profiling and confirmation, although their 48- to 72-hour turnaround limits use in time-sensitive decisions. Immunodiagnostic tests are the fastest-growing category, with a projected CAGR of 7.32% from 2026 to 2031. Lateral-flow and PBP2a assays can deliver results within 5 minutes from blood culture pellets when PCR systems are unavailable.

A 2025 comparative study found that the Clearview PBP2a method identified all mecA-positive isolates in clinical and spiked blood cultures when combined with rapid species identification. This capability positions immunodiagnostic tests as a practical complement to molecular confirmation in resource-constrained settings. The Others category includes MALDI-TOF MS and emerging CRISPR-based tests. MALDI-TOF subtyping from blood culture pellets achieved 59.8% accuracy in MRSA determination, while CRISPR-based methods showed high pooled diagnostic performance in a 2025 review. FDA performance controls favor developers that meet established validation requirements.

Complete Report Scope:

• By Test Type
  • Molecular Diagnostic Tests
  • Immunodiagnostic Tests
  • Culture-Based Tests
  • Others
• By Product Type
  • Instruments
  • Reagents and Kits
• By End User
  • Hospitals and Clinics
  • Diagnostic and Pathology Laboratories
  • Academic and Research Institutes
  • Pharmaceutical and Contract Research Laboratories
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 42.80% of the MRSA testing market share in 2025. Established hospital-onset surveillance, preoperative screening, and antibiotic stewardship programs in the United States and Canada support diagnostic testing before surgery, at admission, and during suspected transmission events. A CDC analysis across six surveillance sites found that community-associated MRSA incidence increased before the pandemic and that hospital-onset incidence remained above prepandemic levels in 2021 and 2022. Canada has recorded a sustained increase in community-associated MRSA bloodstream infection rates since 2019, while Mexico and South America remain earlier-stage markets where culture-based methods are widely used alongside emerging automated molecular platforms.

Europe presents a mixed demand environment for the MRSA testing market. The European Union recorded an MRSA bloodstream infection incidence of 4.48 per 100,000 population in 2024, below the 2030 target of 4.79 per 100,000 population, which may constrain testing growth from hospital-onset infections in Western Europe. However, some Southern, Central, and Eastern European countries reported incidence rates as high as 13.63 per 100,000 population. The United Kingdom, Germany, and France are investing in genome-based surveillance, while CE-IVDR requirements continue to affect product launch timelines across Europe.

Asia-Pacific is the fastest-growing region, with the MRSA testing market projected to expand at a CAGR of 9.89% from 2026 to 2031. Hospital expansion, infection-control requirements, and high MRSA prevalence support growth, while China is expanding molecular capacity in public hospitals, and rural facilities continue to rely on culture-based testing. India’s private hospital chains are deploying PCR-based systems in transplant and orthopedic units, while Japan and South Korea maintain stringent surveillance practices; a 2026 Japanese long-term-care study identified undetected inter-facility MRSA transmission.

List of Companies Covered in this Report:

• Abbott Laboratories
• ALIFAX S.r.l.
• Beckton Dickinson
• bioMérieux
• Bio-Rad Laboratories
• Bruker
• Creative Diagnostics
• Danaher
• DiaSorin
• Roche
• GENSPEED Biotech GmbH
• Hain Lifescience
• Hologic
• Meridian Bioscience, Inc.
• Puritan Medical Products Co. LLC
• QuidelOrtho
• R-Biopharm
• Thermo Fisher Scientific
• Uniogen Oy
• ZeptoMetrix, LLC

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support